ClinicalTrials.gg
Status unknownNCT04518111Updated May 23, 2024

Oxford UKA and HTO Post-market Clinical Study

An observational study in Knee Osteoarthritis, sponsored by Zimmer Biomet. Status unknown at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-05-23.

Sponsored by Zimmer Biomet · Observational

The sponsor has not verified this record recently (last verified May 2024), so the status shown — last known as Enrolling by invitation — may be out of date.
Study type
Observational
Model
Other
Time perspective
Other
Enrollment
370
Ages
18 Years to 85 Years
Sex
All
01

Study summary

The purpose of this study is to compare the performance and safety of medial UKA and HTO in the treatment of AMOA in term of functional outcome, radiographic assessment, range of motion, postoperative complications, revision rate and relevant health economics outcome.

Read the detailed description

The purpose of this study is to compare the outcomes of medial UKA and HTO in the treatment of AMOA by investigating the performance of these 2 procedures in terms of functional outcome, radiographic assessment, range of motion, postoperative complications, revision rate and relevant health economics outcome, then identify factors associated with better clinical performance. It is aimed to provide evidence-based guidelines for selecting the appropriate procedure in managing AMOA in Chinese population based on the findings of this study.

The secondary endpoints will include:

  1. Pain Numerical Rating Scale (NRS)
  2. SF-12 Health Survey
  3. Radiographic assessment includes pre-op and post-op mechanical femorotibial angle (mFTA), patella height, patellofemoral medial and lateral articular surfaces, and displacement angle of patella
  4. Range of motion
  5. Adverse event rate and classification (including complication)
  6. Operating time
  7. Total blood loss (BRECHER formula)
  8. Revision rate

Health economic outcomes based on hospital discharge days, recovery time, physiotherapy and complications/ reoperations will also be analyzed.

02

Conditions studied

  • Knee Osteoarthritis

Keywords

  • Anteromedial osteoarthritis (AMOA)
03

In context

Osteoarthritis, Knee

3,391 studies on the registry are indexed under Osteoarthritis, Knee; 628 are open to participants now.

This study's planned enrollment of 370 is above the median of 100 across 484 observational studies indexed under Osteoarthritis, Knee.

Browse Osteoarthritis, Knee studies →

Lead sponsor

Zimmer Biomet is the lead sponsor of 275 studies on the registry; 28 are open to participants now.

Of its 22 completed or terminated interventional studies of FDA-regulated products, 19 (86%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients who underwent either primary UKA with Oxford Partial Knee with the Microplasty® instrumentation or Open Wedge HTO for AMOA, and meet the inclusion criteria and do not meet any exclusion criteria will be screened to this study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient is aged 18 to 85 years old, inclusive;
  2. Patients who diagnosed with AMOA of the knee, and have undergone Open Wedge HTO, or primary unilateral partial knee arthroplasty with Oxford Partial Knee with Microplasty® instrumentation in accordance to indications of UKA and the following radiographic assessments in the knee joint:

    • exposed bone on both the femur and tibia in the medial compartment.
    • functionally intact ACL
    • full thickness lateral cartilage (ignore osteophytes)
    • functionally normal MCL: correctable deformity (normal medial opening)
    • acceptable patellofemoral joint: normal, medial facet OA with or without bone loss, lateral facet OA without bone loss.
  3. UKA or HTO procedure completed one year prior to study participation;
  4. Patient provides written informed consent by signing and dating the Institutional Review Board/Ethics Committee (IRB/EC) approved informed consent form.

Exclusion criteria

Exclusion Criteria:

  1. Has undergone UKA but met any of the contraindications included in the product labeling of Oxford Partial Knee system;
  2. Has rheumatoid arthritis or other forms of inflammatory joint disease;
  3. Uncooperative or with neurologic disorders who are incapable of following directions;
  4. Has a diagnosed systemic disease that could affect his/her safety or the study outcome;
  5. Anterior cruciate ligament and posterior cruciate ligament injury, collateral ligament instability;
  6. Known to be pregnant;
  7. Prisoner or known alcohol / drug abuser.
05

Study design

Observational model
Other
Time perspective
Other
Enrollment
370 participants (estimated)
Patient registry
No

Groups and cohorts

  • Unicompartmental Knee Arthroplasty (UKA)

    Patients who underwent primary UKA with Oxford Partial Knee with the Microplasty® instrumentation for AMOA.

  • High Tibial Osteotomy (HTO)

    Patients who underwent Open Wedge HTO for AMOA.

06

What researchers measure

Primary outcomes

  1. Oxford Knee Score

    Oxford Knee Score is a patient reported outcome measure questionnaire with a total score range from 0 (severe arthritis) to 48 (satisfactory joint function). The questionnaire contains 12 questions, each with five options scoring from 0 to 4 with 4 being the best outcome for each question.

    Time frame: 2 years

Secondary outcomes

  1. Numerical Rating Scale (NRS)

    The Numeric Rating Scale (NRS) is a measure of pain intensity in adults that consists of a numeric version of the visual analog scale numbers between 0 and 10 where 0 indicates "no pain" and 10 indicates "maximum pain". Respondents select a whole one number between 0 and 10, which is best representative of their pain intensity with higher scores indicating greater pain intensity.

    Time frame: Pre-op, Post-op 1 month, 3 month, 6 month, 1 year and 2 year

  2. SF-12 Health Survey

    The Short Form-12 Health Survey (SF-12) measures generic health concepts relevant across age, disease, and treatment groups. It was designed to measure general health status from the patient's point of view and includes 8 concepts commonly represented in health surveys: physical functioning, role functioning physical, bodily pain, general health, vitality, social functioning, role functioning emotional, and mental health. Two summary scores are reported from the SF-12, namely a mental component score (MCS-12) and a physical component score (PCS-12). All subscale scores were transformed to a 0 to 100 scale with the higher score indicating less dysfunction, impairment, or pain.

    Time frame: Pre-op, Post-op 1 month, 3 month, 6 month, 1 year and 2 year

  3. Mechanical femorotibial angle (mFTA)

    Mechanical femorotibial angle is a measurement that assess the mechanical alignment of the lower limb using the long-leg radiograph. It is the lesser angle intersecting the mechanical femoral axis (the line from the center of the femoral head to the knee center) and the mechanical tibial axis (the line from the knee center to the ankle center).

    Time frame: Pre-op, Post-op 1 month, 3 month, 6 month, 1 year and 2 year

  4. Range of motion

    Measurement of flexion and extension degree of the affected joint.

    Time frame: Pre-op, Post-op 1 month, 3 month, 6 month, 1 year and 2 year

  5. Adverse event rate and classification

    Summary of adverse events recorded during the study period, including complication and reoperation.

    Time frame: Intra-op, post-op 1 year and 2 year

07

Study locations

1 site
  • Beijing Chaoyang Emergency Medical Center
    Beijing, 110105, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04518111
Lead sponsor
Zimmer Biomet
Responsible party
Sponsor
First posted
Aug 19, 2020
Start date
Apr 24, 2021
Primary completion
Sep 30, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
May 23, 2024

Study contacts

Ye Huang
principal investigator · Beijing Chaoyang Emergency Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion